drugset / Trial / NCT02181673

A Study of Golimumab in Participants With Active Psoriatic Arthritis

NCT02181673

Phase 3 Completed 480 enrolled Janssen Research & Development, LLC
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate the efficacy of intravenously (administration of a fluid into the vein) administered golimumab 2 milligram per kilogram (mg/kg) in participants with active psoriatic arthritis (a chronic inflammatory arthritis that is associated with psoriasis).

Timeline

Start
2014-09-08
Primary completion
2016-05-05
Completion
2017-03-22

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Golimumab Monoclonal antibody 2 mg/kg

Indications